ArticleSurgical neurology international2026
Risk of clopidogrel resistance in endovascular aneurysm stenting.
Article in Surgical neurology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thromboembolic complications remain a significant risk in endovascular aneurysm stenting, with clopidogrel resistance implicated as a major contributing factor. The efficacy of ticagrelor as an alternative in clopidogrel non-responders requires further evaluation. The objective of this study is to evaluate thromboembolic outcomes in clopidogrel-resistant patients undergoing endovascular aneurysm stenting and to assess whether switching to ticagrelor mitigates these risks. Methods: This single-center retrospective cohort study included 228 patients treated between 2020 and 2024. All patients underwent P2Y12 testing before the procedure. Clopidogrel non-responders (<40% inhibition) were switched to ticagrelor. The primary endpoint was thromboembolic complication, defined as radiological or clinical infarct, aiming to capture all patients with thromboembolic complication, whether symptomatic or not. Secondary analyses evaluated aneurysm characteristics and associated risk factors. Results: Of the 228 patients, a significant 122 patients (54%) were found to be non-responders and switched to ticagrelor. No statistically significant differences were observed in rates of clinical infarct (13% vs. 11%, Conclusion: Preoperative platelet function testing and switching clopidogrel non-responders to ticagrelor resulted in comparable thromboembolic complication rates to clopidogrel responders. These findings support the role of routine platelet function testing and individualized antiplatelet management in endovascular aneurysm treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.